Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05844033 · ClinicalTrials.gov registry record
Biomarker for Infection Risk in CLL and MM
A clinical trial of Multiple Myeloma and Chronic Lymphocytic Leukemia, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT05844033: Active study of Multiple Myeloma and Chronic Lymphocytic Leukemia, sponsored by Massachusetts General Hospital.
NCT05844033 is a study of Multiple Myeloma and Chronic Lymphocytic Leukemia that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 150 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05844033, a study of Multiple Myeloma and Chronic Lymphocytic Leukemia, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this research study is to use advanced immunology laboratory analysis to identify a more precise blood test that will predict infection risk in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) or Multiple Myeloma (MM).
Primary Outcome
Defined as the number of All-Grade infections per person-years per CTCAE version 5.0 for all participants.
Conditions Studied
Interventions
- OTHER Screening
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2027-03-31 |
What the registry record for NCT05844033 still lists
NCT05844033 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Screening is the first listed.
NCT05844033 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05844033 about?
NCT05844033 is a clinical study titled "Biomarker for Infection Risk in CLL and MM". The aim of this research study is to use advanced immunology laboratory analysis to identify a more precise blood test that will predict infection risk in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) or Multiple Myeloma (MM).
What is the current status of trial NCT05844033?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2023-08-01. Estimated completion is 2027-03-31.
What conditions does trial NCT05844033 study?
This clinical trial studies the following conditions: Multiple Myeloma, Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT05844033?
The interventions under investigation include: Screening (OTHER).
Who is sponsoring clinical trial NCT05844033?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05844033 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05844033's enrollment target sits among peer trials
150 134th of 438 higher than 305 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI